Financial Advocates Investment Management’s Matinas BioPharma MTNB Stock Holding History

Financial Advocates Investment Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$4.7K	–	748
2023 Q1	$4.7K	Hold	200	–	–	﹤0.01%	741
2022 Q4	$5K	Hold	200	–	–	﹤0.01%	750
2022 Q3	$6K	Hold	200	–	–	﹤0.01%	746
2022 Q2	$8K	Hold	200	–	–	﹤0.01%	681
2022 Q1	$8K	Hold	200	–	–	﹤0.01%	727
2021 Q4	$10K	Hold	200	–	–	﹤0.01%	764
2021 Q3	$13K	Hold	200	–	–	﹤0.01%	738
2021 Q2	$8K	Hold	200	–	–	﹤0.01%	732
2021 Q1	$11K	Hold	200	–	–	﹤0.01%	746
2020 Q4	$14K	Hold	200	–	–	﹤0.01%	713
2020 Q3	$8K	Hold	200	–	–	﹤0.01%	626
2020 Q2	$8K	Hold	200	–	–	﹤0.01%	605
2020 Q1	$6K	Hold	200	–	–	﹤0.01%	476
2019 Q4	$23K	Buy	+200	New	+$11.6K	﹤0.01%	508

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Financial Advocates Investment Management's MTNB Position: Q2 2023 in Review

Financial Advocates Investment Management sold out of Matinas BioPharma (MTNB) in Q2 2023, closing a stake of 200 shares — an estimated $4.7K sold.

Financial Advocates Investment Management first reported a position in MTNB in Q4 2019 and held it in 14 quarters. The position peaked at $23K in Q4 2019. 51 funds tracked by Wall St. Rank hold MTNB as of Q2 2023.

Financial Advocates Investment Management reported no remaining Matinas BioPharma position as of Q2 2023 after selling out during the quarter.
Financial Advocates Investment Management sold 200 Matinas BioPharma shares in Q2 2023, an estimated $4.7K.
Financial Advocates Investment Management first reported a position in Matinas BioPharma in Q4 2019 and held it in 14 quarters.
Financial Advocates Investment Management's Matinas BioPharma position peaked at $23K in Q4 2019.
51 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2023.

Based on Financial Advocates Investment Management's 13F filing for Q2 2023, filed 7 Aug 2023.